This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: CVC, ARO, NVR, PENN, SLB

Verisign (VRSN) downgraded at Citigroup to Neutral from Buy, Citigroup said. $46 price target. Catalysts playing out and risk/reward more balanced.

Walgreen Company (WAG) downgraded at UBS to Neutral from Buy, UBS said. $37 price target. Moving to sidelines following ESRX settlement.

STOCK COMMENTS / EPS CHANGES

athenahealth (ATHN) target raised at Jefferies. Shares of ATHN now seen reaching $85, Jefferies said. Recent HMA win validates ability to compete. Hold rating.

Baker Hughes (BHI) numbers raised at UBS. Shares of BHI now seen reaching $65, UBS said. Estimates also increased on solid N. Am results. Buy rating.

CME Group (CME) numbers cut at Citigroup. Shares of CME now seen reaching $58, Citigroup said. Estimates also lowered as volume environment remains challenging. Buy rating.

Coach (COH) numbers lowered at UBS. Shares of COH now seen reaching $63, UBS said. Estimates also lowered on weakening US growth outlook. Neutral rating.

Cytec (CYT) estimates, target cut at Keybanc. Shares of CYT now seen reaching $80, according to Keybanc. Estimates also reduced, given the sale of the coatings resin business. Buy rating.

First Horizon (FHN) numbers reduced at Credit Suisse. FHN estimates were cut through 2014, Credit Suisse said. Company is seeing lower fee income and higher costs. Outperform rating and new $9 price target.

General Electric (GE) estimates lowered at Morgan Stanley through 2014, Morgan Stanley said. Backlog is flattening. Equal-weight rating and $22 price target.

Google (GOOG) estimates raised at Oppenheimer through 2013, Oppenheimer said. Updating model for Motorola Mobility acquisition. Outperform rating.

Johnson Controls (JCI) numbers reduced at Morgan Stanley. JCI estimates were cut through 2014, Morgan Stanley said. Company lacks near-term catalysts. Overweight rating and new $38 price target.

Manpower (MAN) estimates, target cut at BofA/Merrill. Shares of MAN now seen reaching $45, according to Bank of America/Merrill Lynch said. Estimates also reduced, given slower growth in Europe. Outperform rating.

Marriott (MAR) cut from Conviction Buy List at Goldman. RevPAR growth is below the broader industry.

MDC (MDC) added to Conviction Buy List at Goldman. $50 price target. Strong housing recovery appears to be starting.

Onyx Pharmaceuticals (ONXX) numbers increased at Goldman. ONXX estimates were raised through 2015, Goldman Sachs said. Kyprolis is coming to market sooner than expected and should have better pricing. Buy rating and new $85 price target.

Philip Morris International (PM) numbers raised at Jefferies. Shares of PM now seen reaching $92, Jefferies said. Estimates also raised on solid earnings. Hold rating.

Suntrust (STI) estimates, target raised at Credit Suisse. Shares of STI now seen reaching $27, according to Credit Suisse. Estimates also increased, as the company is seeing higher mortgage banking and trading revenue. Outperform rating.

Xerox (XRX) estimates, target reduced at Morgan Stanley. XRX estimates were cut through 2013, given a weaker macro outlook. Neutral rating and new $8 price target.

>To submit a news tip, email: tips@thestreet.com.

READERS ALSO LIKE:


Follow TheStreet on Twitter and become a fan on Facebook.

This article was written by a staff member of TheStreet.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ARO $2.03 -3.30%
CVC $25.19 -0.47%
NVR $1,372.00 0.12%
PENN $16.78 0.00%
SLB $90.10 -0.99%

Markets

DOW 18,086.55 -76.44 -0.42%
S&P 500 2,117.56 -5.92 -0.28%
NASDAQ 5,095.1730 -11.42 -0.22%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs